The iconic rise of Viagra has consistently remained a example of pharmaceutical success, however its legacy within the broader market now triggers questions about long-term returns . Copycat versions are undercutting exclusivity , leading to worries that investing in companies heavily reliant to Viagra's once-dominant position could be a speculativ